MiMedx Group, Inc.

MDXG

US6024961012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
7.8 ^USD	-1.14%		+4.70%	-11.06%

04-30	Transcript : MiMedx Group, Inc., Q1 2024 Earnings Call, Apr 30, 2024
04-30	Earnings Flash (MDXG) MIMEDX GROUP Posts Q1 Revenue $84.7M, vs. Street Est of $79.4M	MT

MiMedx Group, Inc. Announces the Resignation of Rohit Kashyap as President, Wound Care and Surgical, Effective January 3, 2023

December 16, 2022 at 04:19 pm

MiMedx Group, Inc. announced that Dr. Rohit Kashyap, President, Wound Care and Surgical tendered a letter indicating that he is resigning from his position at the Company effective January 3, 2023.

Latest news about MiMedx Group, Inc.

Transcript : MiMedx Group, Inc., Q1 2024 Earnings Call, Apr 30, 2024	04-30
Earnings Flash (MDXG) MIMEDX GROUP Posts Q1 Revenue $84.7M, vs. Street Est of $79.4M	04-30	MT
Earnings Flash (MDXG) MIMEDX GROUP Posts Q1 EPS $0.07, vs. Street Est of $0.04	04-30	MT
MiMedx Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-30	CI
MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products	03-27	MT
MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit	03-27	DJ
MiMedx Group, Inc. Provides Update on AXIOFILL Request for Designation from FDA	03-27	CI
MiMedx Group to Buy Distribution Rights for TELA Bio's Wound Care Product	03-20	MT
MiMedx Launches E-Commerce Platform	03-13	MT
Mimedx Introduces E-Commerce and Account Management Platform	03-13	CI
Lake Street Starts MiMedx Group With Buy Rating, $12 Price Target	03-07	MT
MiMedx Group, Inc. Announces Appointment of New Independent Directors	03-04	CI
Mizuho Securities Raises Price Target on MiMedx to $14 From $13, Maintains Buy Rating	03-01	MT
Spectral AI Names Peter Carlson Chief Executive Officer; Reaffirms 2024 Preliminary Revenue Guidance	03-01	MT
Transcript : MiMedx Group, Inc., Q4 2023 Earnings Call, Feb 28, 2024	02-28
Earnings Flash (MDXG) MIMEDX GROUP Posts Q4 Revenue $86.8M, vs. Street Est of $85.2M	02-28	MT
Earnings Flash (MDXG) MIMEDX GROUP Reports Q4 EPS $0.04, vs. Street Est of $0.06	02-28	MT
MiMedx Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
MiMedx Group, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing	01-22	CI
MiMedx reports US FDA warning letter for Axiofill, shares drop	12-29	RE
Stocks to Watch : MiMedx Group, Nokia	12-29	DJ
MiMedx says US FDA's warning letter for Axiofill not related to safety	12-29	RE
MiMedx Group Gets FDA Warning Letter on Axiofill Classification	12-29	DJ
MiMedx Group Converts Series B Preferred Stock to Common Stock, Adds 30 Million Shares	12-28	MT

MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.

Sector

Biotechnology & Medical Research

Calendar

2024-05-28 - Craig Hallum Institutional Investor Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for MiMedx Group, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.8 USD

Average target price

12.68 USD

Spread / Average Target

+62.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Medical Devices

	1st Jan change	Capi.
MIMEDX GROUP, INC.	-11.06%	1.15B
NIBEC CO., LTD.	-20.55%	130M
COLLPLANT BIOTECHNOLOGIES LTD.	-0.78%	72.61M
KIM FOREST ENTERPRISE CO., LTD.	+6.50%	61.29M
BONUS BIOGROUP LTD.	+2.40%	50.98M

Bio Medical Devices

MiMedx Group, Inc.

Equities

MDXG

US6024961012

Biotechnology & Medical Research

MiMedx Group, Inc. Announces the Resignation of Rohit Kashyap as President, Wound Care and Surgical, Effective January 3, 2023

Latest news about MiMedx Group, Inc.

Chart MiMedx Group, Inc.

Company Profile

Income Statement Evolution

Ratings for MiMedx Group, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Medical Devices